Serum concentrations of soluble interleukin 2 receptor in patients with rheumatoid arthritis: effect of second line drugs

A Crilly, Rajan Madhok, John Watson, Hilary A. Capell

Research output: Contribution to journalArticle

Abstract

Serum soluble interleukin 2 receptor (sIL-2R) concentrations reflect lymphocyte activation in vivo. An investigation was carried out to determine if sIL-2R concentrations correlate with existing disease activity parameters in patients with rheumatoid arthritis (RA) and whether these concentrations are modulated by treatment with second line drugs. Seventy nine patients with rheumatoid arthritis with active disease were prospectively treated with sodium aurothiomalate, auranofin, or sulphasalazine. Sequential concentrations of sIL-2R were measured by enzyme linked immunosorbent assay (ELISA). No correlations were observed between sIL-2R concentrations and clinical parameters and there were only moderate associations with concentrations of C reactive protein and the erythrocyte sedimentation rate. Concentrations of sIL-2R did not significantly change with treatment. It is concluded that sIL-2R probably measures an aspect of rheumatoid synovitis distinct from acute phase reactants and is not influenced by treatment with second line drugs.

Original languageEnglish
Pages (from-to)58-60
Number of pages3
JournalAnnals of the Rheumatic Diseases
Volume52
Issue number1
DOIs
Publication statusPublished - Jan 1993
Externally publishedYes

Fingerprint

Interleukin-2 Receptors
Rheumatoid Arthritis
Serum
Pharmaceutical Preparations
Auranofin
Gold Sodium Thiomalate
Sulfasalazine
Immunosorbents
Synovitis
Lymphocytes
Acute-Phase Proteins
Blood Sedimentation
Lymphocyte Activation
Sedimentation
C-Reactive Protein
Assays
Therapeutics
Chemical activation
Enzyme-Linked Immunosorbent Assay
Enzymes

Keywords

  • Arthritis, Rheumatoid
  • Auranofin
  • Blood Sedimentation
  • C-Reactive Protein
  • Gold Sodium Thiomalate
  • Humans
  • Middle Aged
  • Prospective Studies
  • Receptors, Interleukin-2
  • Sulfasalazine

Cite this

@article{761792caa87940eb89f1d574e19a04bf,
title = "Serum concentrations of soluble interleukin 2 receptor in patients with rheumatoid arthritis: effect of second line drugs",
abstract = "Serum soluble interleukin 2 receptor (sIL-2R) concentrations reflect lymphocyte activation in vivo. An investigation was carried out to determine if sIL-2R concentrations correlate with existing disease activity parameters in patients with rheumatoid arthritis (RA) and whether these concentrations are modulated by treatment with second line drugs. Seventy nine patients with rheumatoid arthritis with active disease were prospectively treated with sodium aurothiomalate, auranofin, or sulphasalazine. Sequential concentrations of sIL-2R were measured by enzyme linked immunosorbent assay (ELISA). No correlations were observed between sIL-2R concentrations and clinical parameters and there were only moderate associations with concentrations of C reactive protein and the erythrocyte sedimentation rate. Concentrations of sIL-2R did not significantly change with treatment. It is concluded that sIL-2R probably measures an aspect of rheumatoid synovitis distinct from acute phase reactants and is not influenced by treatment with second line drugs.",
keywords = "Arthritis, Rheumatoid, Auranofin, Blood Sedimentation, C-Reactive Protein, Gold Sodium Thiomalate, Humans, Middle Aged, Prospective Studies, Receptors, Interleukin-2, Sulfasalazine",
author = "A Crilly and Rajan Madhok and John Watson and Capell, {Hilary A.}",
year = "1993",
month = "1",
doi = "10.1136/ard.52.1.58",
language = "English",
volume = "52",
pages = "58--60",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "1",

}

Serum concentrations of soluble interleukin 2 receptor in patients with rheumatoid arthritis : effect of second line drugs. / Crilly, A; Madhok, Rajan; Watson, John ; Capell, Hilary A.

In: Annals of the Rheumatic Diseases, Vol. 52, No. 1, 01.1993, p. 58-60.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum concentrations of soluble interleukin 2 receptor in patients with rheumatoid arthritis

T2 - effect of second line drugs

AU - Crilly, A

AU - Madhok, Rajan

AU - Watson, John

AU - Capell, Hilary A.

PY - 1993/1

Y1 - 1993/1

N2 - Serum soluble interleukin 2 receptor (sIL-2R) concentrations reflect lymphocyte activation in vivo. An investigation was carried out to determine if sIL-2R concentrations correlate with existing disease activity parameters in patients with rheumatoid arthritis (RA) and whether these concentrations are modulated by treatment with second line drugs. Seventy nine patients with rheumatoid arthritis with active disease were prospectively treated with sodium aurothiomalate, auranofin, or sulphasalazine. Sequential concentrations of sIL-2R were measured by enzyme linked immunosorbent assay (ELISA). No correlations were observed between sIL-2R concentrations and clinical parameters and there were only moderate associations with concentrations of C reactive protein and the erythrocyte sedimentation rate. Concentrations of sIL-2R did not significantly change with treatment. It is concluded that sIL-2R probably measures an aspect of rheumatoid synovitis distinct from acute phase reactants and is not influenced by treatment with second line drugs.

AB - Serum soluble interleukin 2 receptor (sIL-2R) concentrations reflect lymphocyte activation in vivo. An investigation was carried out to determine if sIL-2R concentrations correlate with existing disease activity parameters in patients with rheumatoid arthritis (RA) and whether these concentrations are modulated by treatment with second line drugs. Seventy nine patients with rheumatoid arthritis with active disease were prospectively treated with sodium aurothiomalate, auranofin, or sulphasalazine. Sequential concentrations of sIL-2R were measured by enzyme linked immunosorbent assay (ELISA). No correlations were observed between sIL-2R concentrations and clinical parameters and there were only moderate associations with concentrations of C reactive protein and the erythrocyte sedimentation rate. Concentrations of sIL-2R did not significantly change with treatment. It is concluded that sIL-2R probably measures an aspect of rheumatoid synovitis distinct from acute phase reactants and is not influenced by treatment with second line drugs.

KW - Arthritis, Rheumatoid

KW - Auranofin

KW - Blood Sedimentation

KW - C-Reactive Protein

KW - Gold Sodium Thiomalate

KW - Humans

KW - Middle Aged

KW - Prospective Studies

KW - Receptors, Interleukin-2

KW - Sulfasalazine

U2 - 10.1136/ard.52.1.58

DO - 10.1136/ard.52.1.58

M3 - Article

VL - 52

SP - 58

EP - 60

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 1

ER -